Inactive Instrument

Neutra Corp Stock Other OTC

US64129C2044

Pharmaceuticals

End-of-day quote Other OTC
- ^USD	-

25-03-31	Neutra Corp. executed a letter of intent to acquire CuraConnector.com, Inc.	CI
24-08-07	Neutra Corp. Reports Earnings Results for the First Quarter Ended April 30, 2024	CI

Neutra Corp. is an early-stage research and development company. The Company is engaged in marketing and participating in the nutraceutical space by bringing products derived from all natural and organic origins. The Company plans to research and bring new technology to the Nutraceutical space. The Company is primarily focused on participating in the medical cannabis market, which is a nutraceutical sub-market. It intends to entrust the manufacturing to a nutraceutical contractor to private label all of its products and to sell them under its brand. It primarily sells hemp-derived products, including products containing delta-8-THC and other cannabinoids. Its subsidiaries include Diamond Anvil Designs, LLC, Deity Corporation and Vivis Corporation.

Employees

Sector

Pharmaceuticals

More about the company

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!

SEIZE THE OFFER!

Market Cap	460K 401K 379K 345K 644K 44.07M 647K 4.52M 1.75M 22.4M 1.73M 1.69M 71.69M	P/E 2023	-1.94x	P/E 2024	-3.75x
Enterprise Value	525K 457K 432K 393K 734K 50.25M 738K 5.15M 1.99M 25.54M 1.97M 1.93M 81.74M	EV / Sales 2023	18,402,377x	EV / Sales 2024	23,773,714x
Free-Float	99.31%	Yield 2023 *	-	Yield 2024	-

25-03-31	Neutra Corp. executed a letter of intent to acquire CuraConnector.com, Inc.	CI
24-08-07	Neutra Corp. Reports Earnings Results for the First Quarter Ended April 30, 2024	CI
24-08-02	Neutra Corp. Reports Earnings Results for the Full Year Ended January 31, 2024	CI
23-12-15	Neutra Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2023	CI
23-09-14	Neutra Corp. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2023	CI
23-06-22	Neutra Corp. Reports Earnings Results for the First Quarter Ended April 30, 2023	CI
23-06-09	Neutra Corp. Reports Earnings Results for the Full Year Ended January 31, 2023	CI
23-06-08	Neutra Corp. Auditor Raises 'Going Concern' Doubt	CI
23-01-29	Neutra Corp. executed a binding letter of intent to acquire Mercury Clinical Research, Inc.	CI
22-12-15	Neutra Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022	CI
22-09-14	Neutra Corp. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2022	CI
22-06-21	Neutra Corp. Reports Earnings Results for the First Quarter Ended April 30, 2022	CI
22-05-10	Neutra Corp. Reports Earnings Results for the Full Year Ended January 31, 2022	CI

09-14	Neutra Corp's Neutra Life Sciences Expands 2026 Industry Conference Schedule to Deepen Sponsor and CRO Relationships Across Its Site Network	AQ
07-13	Neutra Corp Targets Expanded Sponsor and CRO Relationships in Q3 & Q4 2026, Reaffirming Full Commitment to Life Sciences Growth	AQ
06-29	Neutra Corp’s Subsidiary Neutra Life Sciences Executes New Women’s Health Joint Venture and Expands Trial Portfolio	AQ
01-19	Neutra Corp Successfully Pivots Into New Business Vertical With Projected Over 1,000% Revenue Increase Year-Over-Year	AQ
25-10-13	Neutra Corp's Subsidiary, Neutra Life Sciences, Adds to Its Site Network With New Joint Venture Partnership in Family Medicine	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	+0.59%	+2.03%	+50.74%	+100.57%	1,014B
JOHNSON & JOHNSON	+0.70%	+0.83%	+51.55%	+65.29%	644B
ABBVIE INC.	+0.04%	+2.87%	+18.80%	+70.40%	464B
ROCHE HOLDING AG	-0.36%	+4.54%	+38.71%	+40.03%	354B
NOVARTIS AG	+1.52%	+3.46%	+20.13%	+26.08%	265B
ASTRAZENECA PLC	+2.41%	+5.70%	+9.06%	+15.85%	253B
AMGEN INC.	+0.65%	-0.88%	+38.00%	+44.06%	203B
NOVO NORDISK A/S	+2.48%	-2.43%	-24.40%	-57.05%	186B
GILEAD SCIENCES, INC.	+1.28%	+3.34%	+33.30%	+97.88%	183B
Average	+1.04%	+0.96%	+26.21%	+44.79%	396.31B
Weighted average by Cap.	+0.78%	+1.41%	+34.76%	+61.14%

	2023	2024
Net sales	0.07 0.06 0.06 0.05 0.1 6.51 0.1 0.67 0.26 3.31 0.26 0.25 10.59	0.04 0.03 0.03 0.03 0.06 3.79 0.06 0.39 0.15 1.92 0.15 0.15 6.16
Net income	-561K -489K -463K -420K -786K -53.77M -789K -5.51M -2.13M -27.33M -2.11M -2.06M -87.47M	-233K -203K -192K -175K -327K -22.36M -328K -2.29M -886K -11.36M -877K -858K -36.38M
Net Debt	54.5K 47.47K 44.93K 40.82K 76.26K 5.22M 76.63K 535K 207K 2.65M 205K 200K 8.49M	64.5K 56.18K 53.17K 48.31K 90.25K 6.18M 90.69K 633K 245K 3.14M 242K 237K 10.05M

Neutra Corp Stock Other OTC

Stocks

US64129C2044

Pharmaceuticals

Valuation: Neutra Corp

Latest news: Neutra Corp

Press Releases: Neutra Corp

Managers and Directors: Neutra Corp

Other Pharmaceuticals

Financials

Company Profile